05. July 2018

In part I of this series, I wrote about the financial unsustainability of antibiotics development. Revenues and profits of the new therapies launched since 2010 do not match the costs of development and thus most large pharmaceutical companies and biotech investors have stopped supporting antibiotic development. Fixing the broken business system will require a concerted effort by all stakeholders: payers, physicians, regulators, and the biopharmaceutical industry on a global scale. In this part...